Company intelligence / Profile preview
Advanced BioDesign
Lyon/Saint-Priest, Auvergne-Rhône-Alpes, Francea-biodesign.com ↗
- Ownership
- Private
- Employees
- ~49
- Development stage
- Other
01
Overview
Preliminary results from the ODYSSEY first-in-human study with lead candidate ABD‑3001 in relapsed AML patients show good safety and biological activity at all doses tested. Over 65% of patients showed preliminary signs of efficacy, with some experiencing long-term benefit. The next phase will further assess efficacy over full treatment cycles.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
No major pharma partnerships disclosed as of May 2025; seeking partners for pivotal trials and commercialization.
Beyond the preview
Go deeper on Advanced BioDesign.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Advanced BioDesign.